The efficacy of PARPi therapy was initially demonstrated in high-grade serous ovarian cancer (referred to as OV hereafter) and breast cancer (BC), in which HRD was driven by germline pathogenic variants in either the BRCA1 or BRCA2 genes (2). The gene discussed is BRCA1; the disease is breast carcinoma.